Lars Rydn

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4995707/lars-ryden-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172 papers	19,292 citations	49 h-index	138 g-index
192 ext. papers	23,770 ext. citations	8 avg, IF	5.85 L-index

#	Paper	IF	Citations
172	Endodontic inflammatory disease: A risk indicator for a first myocardial infarction. *International Endodontic Journal*, **2022**, 55, 6-17	5.4	1
171	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. *Cardiovascular Diabetology*, **2022**, 21, 50	8.7	1
170	Guideline Development for Medical Device Technology: Issues for Consideration.. *Journal of Diabetes Science and Technology*, **2022**, 19322968221093355	4.1	
169	Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry. *Cardiovascular Drugs and Therapy*, **2021**, 35, 801-808	3.9	3
168	Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test: Validation of a new screening algorithm in patients with coronary artery disease from the ESC-EORP EUROASPIRE V registry. *Diabetes Research and Clinical Practice*, **2021**, 183, 109156	7.4	0
167	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. *European Heart Journal*, **2021**, 42, 2565-2573	9.5	7
166	Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1677-1680	6.7	1
165	Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial. *Diabetes and Vascular Disease Research*, **2021**, 18, 14791641211002475	3.3	1
164	Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. *Diabetes Research and Clinical Practice*, **2021**, 175, 108796	7.4	2
163	The history of the Nobel prize for the discovery of insulin. *Diabetes Research and Clinical Practice*, **2021**, 175, 108819	7.4	4
162	Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. *Drugs*, **2021**, 81, 1373-1379	12.1	6
161	Peripheral arterial disease and intermittent claudication in coronary heart disease patients. *International Journal of Cardiology*, **2021**, 322, 227-232	3.2	5
160	Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys. *European Journal of Preventive Cardiology*, **2021**,	3.9	4
159	Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. *Cardiovascular Diabetology*, **2021**, 20, 38	8.7	0
158	Copeptin is associated with mortality in elderly people. *European Journal of Clinical Investigation*, **2021**, 51, e13516	4.6	0
157	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. *Diabetes Research and Clinical Practice*, **2021**, 177, 108870	7.4	1
156	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 484-490	18.1	2

155	INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions : In Partnership with the World Heart Federation, European Society of Cardiology, Asia Pacific Society of Cardiology, InterAmerican Society of Cardiology, and PanAfrican Society of Cardiology. *Current Cardiology Reports*, **2021**, 23, 136	4.2	
154	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. *Diabetes Research and Clinical Practice*, **2020**, 170, 108488	7.4	3
153	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. *Lancet Neurology, The*, **2020**, 19, 582-590	24.1	48
152	Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?. *Diabetes and Vascular Disease Research*, **2020**, 17, 1479164120922123	3.3	1
151	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. *Circulation*, **2020**, 141, 1841-1854	16.7	53
150	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. *Diabetes Care*, **2020**, 43, 2242-2247	14.6	4
149	Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. *Diabetes Care*, **2020**, 43, 726-733	14.6	24
148	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. *European Journal of Preventive Cardiology*, **2020**,	3.9	4
147	Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry. *European Journal of Preventive Cardiology*, **2020**,	3.9	6
146	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 106-114	18.1	42
145	Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management. *Diabetes Care*, **2020**, 43, 2001-2009	14.6	7
144	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. *Cardiovascular Diabetology*, **2020**, 19, 199	8.7	3
143	Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. *Diabetes Care*, **2020**, 43, 2853-2858	14.6	4
142	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. *European Journal of Preventive Cardiology*, **2020**, 27, 1630-1636	3.9	11
141	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *European Heart Journal*, **2020**, 41, 255-323	9.5	1360
140	Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504-1511. *Diabetes Care*, **2020**, 43, e9	14.6	
139	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. *European Journal of Preventive Cardiology*, **2020**, 2047487320908698	3.9	25
138	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. *Circulation*, **2019**, 140, 1451-1459	16.7	22

137	The Medical Profession, Industry, and Continuing Medical Education: Finding the Balance That's Right for Patients. *American Journal of Medicine*, **2019**, 132, 921-925	2.4	7
136	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet, The*, **2019**, 394, 121-130	40	917
135	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. *Lancet, The*, **2019**, 394, 131-138	40	228
134	Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. *Diabetes Care*, **2019**, 42, 1504-1511	14.6	8
133	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. *Atherosclerosis*, **2019**, 285, 135-146	3.1	106
132	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. *European Journal of Preventive Cardiology*, **2019**, 26, 824-835	3.9	288
131	Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. *European Journal of Preventive Cardiology*, **2019**, 26, 25-32	3.9	133
130	Risk factor reduction in type 2 diabetes demands a multifactorial approach. *European Journal of Preventive Cardiology*, **2019**, 26, 81-91	3.9	6
129	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. *European Journal of Preventive Cardiology*, **2019**, 26, 73-80	3.9	39
128	The metabolic syndrome - What is it and how should it be managed?. *European Journal of Preventive Cardiology*, **2019**, 26, 33-46	3.9	42
127	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. *European Heart Journal*, **2019**, 40, 2907-2919	9.5	22
126	Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial. *European Journal of Preventive Cardiology*, **2019**, 26, 847-854	3.9	6
125	Attitudes and lifestyle factors in relation to oral health and dental care in Sweden: a cross-sectional study. *Acta Odontologica Scandinavica*, **2019**, 77, 282-289	2.2	3
124	Antiphospholipid Antibodies in Patients With Myocardial Infarction. *Annals of Internal Medicine*, **2019**, 170, 277-280	8	8
123	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. *European Journal of Epidemiology*, **2019**, 34, 247-258	12.1	15
122	A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. *Global Heart*, **2019**, 14, 215-240	2.9	13
121	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). *Circulation*, **2018**, 137, 88-90	16.7	19
120	Effects of enhanced external counterpulsation on skeletal muscle gene expression in patients with severe heart failure. *Clinical Physiology and Functional Imaging*, **2018**, 38, 118-127	2.4	2

119	Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. *Diabetes and Vascular Disease Research*, **2018**, 15, 14-23	3.3	11
118	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. *American Heart Journal*, **2018**, 199, 170-175	4.9	4
117	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. *International Journal of Cardiology*, **2018**, 272, 20-25	3.2	19
116	Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort. *Diabetes and Vascular Disease Research*, **2018**, 15, 387-395	3.3	3
115	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 2522-2533	5.6	4
114	Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology. *Cardiovascular Diabetology*, **2018**, 17, 21	8.7	11
113	On the prognostic value of post-load glucose in patients with coronary artery disease. *European Heart Journal*, **2018**, 39, 2746-2748	9.5	10
112	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. *Diabetes Care*, **2018**, 41, 1792-1800	14.6	17
111	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2018**, 391, 219-229	40	414
110	Effectiveness of different outreach strategies to identify individuals at high risk of diabetes in a heterogeneous population: a study in the Swedish municipality of Sörtälje. *European Journal of Preventive Cardiology*, **2018**, 25, 1990-1999	3.9	4
109	Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data. *Clinical Science*, **2018**, 132, 2003-2012	6.5	7
108	The Accuracy of Point-of-Care Equipment for Glucose Measurement in Screening for Dysglycemia in Patients with Coronary Artery Disease. *Diabetes Technology and Therapeutics*, **2018**, 20, 596-602	8.1	8
107	Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. *Diabetes and Vascular Disease Research*, **2018**, 15, 494-503	3.3	21
106	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 391-402	18.1	42
105	Symptoms of depression and their relation to myocardial infarction and periodontitis. *European Journal of Cardiovascular Nursing*, **2017**, 16, 468-474	3.3	8
104	The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial. *European Journal of Preventive Cardiology*, **2017**, 24, 858-866	3.9	17
103	Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: Insights from the EUROASPIRE IV survey of the European Society of Cardiology. *European Journal of Preventive Cardiology*, **2017**, 24, 1168-1180	3.9	8
102	Saliva and plasma levels of cardiac-related biomarkers in post-myocardial infarction patients. *Journal of Clinical Periodontology*, **2017**, 44, 692-699	7.7	6

101	The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey From the European Society of Cardiology. *Diabetes Care*, **2017**, 40, 1233-1240	14.6	57
100	Corrections needed to 2016 ESC and AHA guidelines on heart failure. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 325-326	18.1	6
99	Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. *Diabetes and Vascular Disease Research*, **2017**, 14, 77-87	3.3	16
98	Updates on cardiovascular outcome trials in diabetes. *Cardiovascular Diabetology*, **2017**, 16, 128	8.7	36
97	Anaemia and iron deficiency in heart failure: epidemiological gaps, diagnostic challenges and therapeutic barriers in sub-Saharan Africa. *Cardiovascular Journal of Africa*, **2017**, 28, 331-337	0.7	
96	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *New England Journal of Medicine*, **2017**, 377, 1319-1330	59.2	1122
95	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 877-886	18.1	164
94	Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013. *Global Heart*, **2017**, 12, 315-322.e3	2.9	62
93	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. *European Journal of Preventive Cardiology*, **2016**, 23, 2007-2018	3.9	96
92	Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure. *Journal of the American College of Cardiology*, **2016**, 68, 1404-1416	15.1	53
91	Oral glucose tolerance testing and cardiovascular disease. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 732-733	18.1	3
90	Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study. *Diabetes and Vascular Disease Research*, **2016**, 13, 307-11	3.3	5
89	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *European Journal of Preventive Cardiology*, **2016**, 23, NP1-NP96	3.9	445
88	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. *European Journal of Preventive Cardiology*, **2016**, 23, 636-48	3.9	549
87	Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study. *Circulation*, **2016**, 133, 576-83	16.7	120
86	Response by Rydén to Letter Regarding Article, "Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study". *Circulation*, **2016**, 134, e2	16.7	2
85	Periodontal disease - important to consider in cardiovascular disease prevention. *Expert Review of Cardiovascular Therapy*, **2016**, 14, 987-9	2.5	14
84	Time-saving screening for diabetes in patients with coronary artery disease: a report from EUROASPIRE IV. *BMJ Open*, **2016**, 6, e013835	3	5

83	Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. *European Journal of Preventive Cardiology*, **2016**, 23, 1618-27	3.9	10
82	Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG. *Clinical Therapeutics*, **2016**, 38, 1279-1287	3.5	15
81	Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF). *International Journal of Cardiology*, **2016**, 220, 750-8	3.2	8
80	Current perspectives on cardiovascular outcome trials in diabetes. *Cardiovascular Diabetology*, **2016** , 15, 139	8.7	51
79	Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes. *Heart*, **2015**, 101, 1139-48	5.1	28
78	Accuracy of a Simplified Glucose Measurement Device--The HemoCue Glucose 201RT. *Diabetes Technology and Therapeutics*, **2015**, 17, 755-8	8.1	10
77	Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study. *European Journal of Preventive Cardiology*, **2015**, 22, 753-61	3.9	18
76	Salivary Matrix Metalloproteinase-8 and -9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and Its Relation to Coronary Artery Disease). *PLoS ONE*, **2015**, 10, e0126370	3.7	32
75	Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. *Diabetes and Vascular Disease Research*, **2015**, 12, 23-32	3.3	34
74	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. *Cardiovascular Diabetology*, **2015**, 14, 133	8.7	74
73	Prevalence and prognostic implications of anaemia and iron deficiency in Tanzanian patients with heart failure. *Heart*, **2015**, 101, 592-9	5.1	16
72	Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology. *European Heart Journal*, **2015**, 36, 1171-7	9.5	58
71	Gu□ de pr□tica cl□ica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraci□ con la European Association for the Study of Diabetes. *Revista Espanola De Cardiologia*, **2014**, 67, 136.e1-136.e56	1.5	8
70	Longitudinal development of left ventricular diastolic function in patients with type 2 diabetes. *Diabetes Care*, **2014**, 37, 3092-7	14.6	13
69	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. *American Heart Journal*, **2014**, 168, 23-9.e2	4.9	46
68	Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2014**, 311, 1515-25	27.4	177
67	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management. *Diabetes and Vascular Disease Research*, **2014**, 11, 395-409	3.3	11
66	The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study. *Diabetes and Vascular Disease Research*, **2014**, 11, 290-293	3.3	10

65	Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls. *PLoS ONE*, **2014**, 9, e113740	3.7	24
64	Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study. *Heart*, **2014**, 100, 1235-41	5.1	63
63	Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 627-33	18.1	54
62	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *European Heart Journal*, **2013**, 34, 3035-87	9.5	1444
61	Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes. *European Journal of Preventive Cardiology* , **2013**, 20, 549-54	3.9	22
60	Self-rated health predicts outcome in patients with type 2 diabetes and myocardial infarction: a DIGAMI 2 quality of life sub-study. *Diabetes and Vascular Disease Research*, **2013**, 10, 361-7	3.3	13
59	Satisfaction with glucose-lowering treatment and well-being in patients with type 2 diabetes and myocardial infarction: a DIGAMI2 QoL sub-study. *Diabetes and Vascular Disease Research*, **2013**, 10, 263-9	3.3	6
58	Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. *Journal of Hypertension*, **2013**, 31, 414-21	1.9	52
57	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Atherosclerosis*, **2012**, 223, 1-68	3.1	286
56	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *European Heart Journal*, **2012**, 33, 1635-701	9.5	2797
55	Glucose perturbations and cardiovascular risk: challenges and opportunities. *Diabetes and Vascular Disease Research*, **2012**, 9, 170-6	3.3	16
54	Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study. *Diabetes and Vascular Disease Research*, **2012**, 9, 287-95	3.3	10
53	Mortality prediction in the elderly by an easily measured metabolic index. *Diabetes and Vascular Disease Research*, **2012**, 9, 226-33	3.3	2
52	Joint ESC/EASD guidelines on diabetes, where are we now and where should we go?. *Current Vascular Pharmacology*, **2012**, 10, 690-2	3.3	2
51	The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes. *Diabetes and Vascular Disease Research*, **2011**, 8, 143-9	3.3	
50	Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). *Circulation*, **2011**, 124, 1727-36	16.7	121
49	Diabetes, prediabetes and cardiovascular risk. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2010**, 17 Suppl 1, S9-14		44
48	Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the euro heart survey on diabetes and the heart. *European Heart Journal*, **2010**, 31, 3040-5	9.5	47

47	The impact of infarct type on the reliability of early oral glucose tolerance testing in patients with myocardial infarction. *International Journal of Cardiology*, **2010**, 145, 259-260	3.2	12
46	Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting. *Reviews in Endocrine and Metabolic Disorders*, **2010**, 11, 87-94	10.5	8
45	Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?. *Nature Clinical Practice Endocrinology and Metabolism*, **2009**, 5, 8-9		1
44	Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. *Diabetes and Vascular Disease Research*, **2009**, 6, 71-9	3.3	14
43	A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study. *European Journal of Heart Failure*, **2009**, 11, 39-47	12.3	49
42	A gluco-metabolic risk index with cardiovascular risk stratification potential in patients with coronary artery disease. *Diabetes and Vascular Disease Research*, **2009**, 6, 62-70	3.3	7
41	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). *American Heart Journal*, **2008**, 155, 26-32, 32.e1-6	4.9	146
40	Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes. *European Journal of Heart Failure*, **2008**, 10, 1080-7	12.3	45
39	Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study. *Diabetes Care*, **2008**, 31, 36-8	14.6	69
38	Implications of abnormal glucose metabolism in patients with coronary artery disease. *Diabetes and Vascular Disease Research*, **2008**, 5, 285-90	3.3	15
37	Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. *European Heart Journal*, **2008**, 29, 1753-60	9.5	75
36	Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2008**, 15, 216-23		65
35	What are the risk factors for progression of coronary artery calcification in patients with type 2 diabetes?. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, 370-1		2
34	The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvements. *Blood Pressure*, **2008**, 17, 250-9	1.7	5
33	Cardiovascular prevention in patients with diabetes and prediabetes. *Herz*, **2008**, 33, 170-7	2.6	13
32	Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. *European Heart Journal*, **2008**, 29, 177-84	9.5	79
31	The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. *European Heart Journal*, **2008**, 29, 166-76	9.5	120
30	Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases: Executive Summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). *Revista Espanola De Cardiologia (English Ed)*, **2007**, 60, 525	0.7	10

29	Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. *Heart*, **2007**, 93, 1577-83	5.1	111
28	Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply. *European Heart Journal*, **2007**, 28, 1402-1402	9.5	329
27	European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *European Journal of Cardiovascular Prevention and Rehabilitation*, **2007**, 14 Suppl 2, S1-113		751
26	Management of coronary artery disease in patients with and without diabetes mellitus: Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2007**, 14, 29-36		32
25	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *European Journal of Cardiovascular Prevention and Rehabilitation*, **2007**, 14 Suppl 2, E1-40		309
24	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *European Heart Journal*, **2007**, 28, 88-136	9.5	889
23	Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. *European Heart Journal*, **2006**, 27, 2969-74	9.5	130
22	Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2005**, 12, 465-71		31
21	The association between glucose abnormalities and heart failure in the population-based Reykjavik study. *Diabetes Care*, **2005**, 28, 612-6	14.6	217
20	Patient access to medical technology across Europe. *European Heart Journal*, **2004**, 25, 611-6	9.5	19
19	The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. *European Heart Journal*, **2004**, 25, 1880-90	9.5	394
18	Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. *Journal of the American College of Cardiology*, **2004**, 43, 585-91	15.1	216
17	Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. *Journal of Cardiovascular Pharmacology*, **2004**, 44, 101-8	3.1	34
16	Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. *Diabetes Care*, **2003**, 26, 2770-6	14.6	92
15	Arne Larsson 1915–2001. *PACE - Pacing and Clinical Electrophysiology*, **2002**, 25, 521-521	1.6	
14	Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. *Lancet, The*, **2002**, 359, 2140-4	40	791
13	Reduction of hospital days by biventricular pacing. *European Journal of Heart Failure*, **2000**, 2, 399-406	12.3	40
12	Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. *Circulation*, **2000**, 102, 611-6	16.7	255

11	Ramipril reduced mortality and cardiovascular morbidity in high-risk adults. *ACP Journal Club*, **2000**, 132, 41		
10	The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion. *Cardiovascular Drugs and Therapy*, **1999**, 13, 347-53	3.9	9
9	Coronary venous drug infusion in the ischaemic-reperfused isolated rat heart. *Cardiovascular Research*, **1996**, 31, 82-92	9.9	0
8	Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. *Journal of the American College of Cardiology*, **1995**, 26, 57-65	15.1	1197
7	Quality-of-life in patients treated with atrioventricular synchronous pacing compared to rate modulated ventricular pacing: a long-term, double-blind, crossover study. *PACE - Pacing and Clinical Electrophysiology*, **1992**, 15, 1467-76	1.6	60
6	A double-blind study of submaximal exercise tolerance and variation in paced rate in atrial synchronous compared to activity sensor modulated ventricular pacing. *PACE - Pacing and Clinical Electrophysiology*, **1992**, 15, 905-15	1.6	29
5	Holter documented sudden death in a patient with an implanted defibrillator. *PACE - Pacing and Clinical Electrophysiology*, **1992**, 15, 1008-14	1.6	46
4	Longevity in patients with high degree atrioventricular block paced in the atrial synchronous or the fixed rate ventricular inhibited mode. *PACE - Pacing and Clinical Electrophysiology*, **1992**, 15, 304-13	1.6	41
3	Long-term cardiovascular effects of metoprolol therapy: a review article. *Journal of Clinical Pharmacology*, **1990**, 30, S118-23	2.9	5
2	Metoprolol CR/ZOK. *Journal of Clinical Pharmacology*, **1990**, 30, S1-S1	2.9	
1	Efficacy of epanolol versus metoprolol in angina pectoris. Results from the Swedish Multicenter Study of Exercise Tolerance. The Swedish Multicenter Study Group. *Drugs*, **1989**, 38 Suppl 2, 66	12.1	